KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Expenses (2017 - 2026)

Amneal Pharmaceuticals has reported Operating Expenses over the past 9 years, most recently at $183.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses changed 0.16% year-over-year to $183.7 million; the TTM value through Dec 2025 reached $717.2 million, up 7.13%, while the annual FY2025 figure was $717.2 million, 7.13% up from the prior year.
  • Operating Expenses for Q4 2025 was $183.7 million at Amneal Pharmaceuticals, down from $201.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $201.3 million in Q3 2025 and troughed at $139.0 million in Q2 2021.
  • A 5-year average of $157.4 million and a median of $152.5 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: rose 19.65% in 2021 and later decreased 7.16% in 2023.
  • Year by year, Operating Expenses stood at $150.2 million in 2021, then dropped by 4.47% to $143.5 million in 2022, then grew by 8.19% to $155.2 million in 2023, then grew by 18.2% to $183.4 million in 2024, then increased by 0.16% to $183.7 million in 2025.
  • Business Quant data shows Operating Expenses for AMRX at $183.7 million in Q4 2025, $201.3 million in Q3 2025, and $173.3 million in Q2 2025.